What did U.S. Renal Care pay for Ulster Dialysis?

U.S. Renal Care acquired Ulster Dialysis for $2.3M in 2024 (5.8x EBITDA), equivalent to 0.50x revenue. Target revenue was approximately $4.6M. Target EBITDA was approximately $0.4M.

What does Ulster Dialysis do?

Ulster Dialysis is a medical practice specialty business.

What multiple did U.S. Renal Care pay for Ulster Dialysis?

5.8x EBITDA and 0.50x revenue, based on disclosed deal value of $2.3M and disclosed financials.

M&A TRANSACTION · 2024

Ulster Dialysis acquired by U.S. Renal Care

$2.3M· 5.8x EBITDA· 0.50x revenue

Target

Ulster Dialysis

Acquirer

U.S. Renal Care

Strategic buyer

Disclosed financials at time of acquisition

Revenue

$4.6M

EBITDA

$0.4M

Deal Value

$2.3M

EV/EBITDA

5.8x

Context

This $2.3M acquisition of Ulster Dialysis by U.S. Renal Care sits in the medical practice specialty sub-vertical. The 5.8x EBITDA multiple paid in 2024 can be compared against the population median for medical practice specialty transactions of similar size on our Medical Practice Specialty valuation hub. U.S. Renal Care is acquiring as a strategic buyer; see how strategic acquirers typically price medical practice specialty businesses on our Medical Practice Specialty strategic buyer-pool page.

Source

Data sourced from CON filings. All figures reflect disclosed values at the time of the acquisition; no estimated or imputed data. Methodology

Value your own medical practice specialty

Get an instant valuation range for your business. Backed by 25,592 real M&A transactions.

Compare your business to the Ulster Dialysis acquisition.

Citation: ExitValue.ai. (2024). Ulster Dialysis acquired by U.S. Renal Care. https://exitvalue.ai/deals/ulster-dialysis-acquired-by-us-renal-care-hc-2024-0018